Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Recursion uses artificial intelligence and automated lab experiments to discover new medicines faster and cheaper than traditional drug research.
Recursion is a drug discovery company that uses computers and robots to find new medicines. Instead of scientists guessing which molecules might work, Recursion runs thousands of experiments in its own automated labs and lets artificial intelligence spot patterns that humans would miss.
The basic idea works like this: the company tests huge numbers of small chemical compounds on living cells, then takes microscopic pictures of what happens. Its software compares those pictures across millions of experiments to learn which compounds push cells in useful directions — say, toward killing a cancer cell or protecting a sick one. That library of knowledge becomes a search engine for drug candidates. Recursion also bought two smaller biotech companies, Cyclica and Valence, to add chemistry and protein-structure tools to its platform. Recursion makes money in two ways. Its own pipeline of experimental drugs, some now in clinical trials, could eventually earn billions if any reach the market. It also signs deals with big pharmaceutical partners who pay upfront fees and milestone payments to use Recursion's platform and share in the resulting drugs. Those partnerships with companies like Bayer and Sanofi bring in cash while the internal pipeline matures. Like most clinical-stage biotechs, Recursion burns through money on research and trials and has posted steep losses, funding itself largely through stock sales.
The bet is that faster, cheaper discovery beats the old slow grind of lab-by-lab trial and error. The risk is that AI-discovered drugs still have to prove themselves in human trials, and until one does, the platform's promise remains a promise.
Saved answer · last researched 15 Nov 2026